William H Ward1, Elin R Sigurdson2, Andrew C Esposito3, Karen J Ruth4, Samuel M Manstein3, Eric C Sorenson2, Brian D Wernick5, Jeffrey M Farma2. 1. Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. Electronic address: william.ward@fccc.edu. 2. Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 3. Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania. 4. Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania. 5. Department of Surgery, St. Luke's University Health Network, Bethlehem, Pennsylvania.
Abstract
BACKGROUND: Despite advances in the treatment of rectal adenocarcinoma, the management of locally advanced disease remains a challenge. The standard of care for patients with stages II and III rectal cancer includes neoadjuvant chemoradiation followed by total mesorectal excision and postoperative chemotherapy. Much effort has been dedicated to the identification of predictive factors associated with pathologic complete response (pCR). The aim of our study was to examine our institutional experience and determine whether any association exists between anatomic tumor location and the rate of pCR. We hypothesized that lesions more than 6 cm from the anal verge are more likely to achieve a pCR. METHODS: Using data from our prospectively maintained tumor registry, a query was completed to identify all patients with locally advanced rectal adenocarcinoma who underwent treatment at Fox Chase Cancer Center from 2002 to 2015. Demographics, pretreatment, posttreatment, and final pathologic TNM staging data were collected as well as treatment intervals in days, recurrence status, overall survival, and disease-free survival. Patients with incomplete endoscopic data, staging information, survival, or recurrence status were excluded. The primary outcome measured was the degree of pathologic response. Logistic regression was used to adjust for covariates. RESULTS: Of the 135 patients eligible in the study cohort, 39% were female and 61% were male. Regarding initial clinical stage, 43% were stage II and 57% were stage III. A total of 29% had a pCR, 43% had partial pathologic response, and 28% had no response to neoadjuvant treatment. Tumor location ranged from 0 to 13 cm from the anal verge. Longitudinal tumor length was recorded in 111 patients, facilitating the calculation of mean tumor distance from the anal verge. This ranged from 0 to 15.5 cm. Univariate and multivariable analyses were completed using pCR as a primary outcome. No statistically significant difference was noted based on tumor location, regardless of measurement approach. CONCLUSIONS: Anatomic location of cancer of the rectum does not affect pCR after neoadjuvant therapy and subsequent surgical resection. Published by Elsevier Inc.
BACKGROUND: Despite advances in the treatment of rectal adenocarcinoma, the management of locally advanced disease remains a challenge. The standard of care for patients with stages II and III rectal cancer includes neoadjuvant chemoradiation followed by total mesorectal excision and postoperative chemotherapy. Much effort has been dedicated to the identification of predictive factors associated with pathologic complete response (pCR). The aim of our study was to examine our institutional experience and determine whether any association exists between anatomic tumor location and the rate of pCR. We hypothesized that lesions more than 6 cm from the anal verge are more likely to achieve a pCR. METHODS: Using data from our prospectively maintained tumor registry, a query was completed to identify all patients with locally advanced rectal adenocarcinoma who underwent treatment at Fox Chase Cancer Center from 2002 to 2015. Demographics, pretreatment, posttreatment, and final pathologic TNM staging data were collected as well as treatment intervals in days, recurrence status, overall survival, and disease-free survival. Patients with incomplete endoscopic data, staging information, survival, or recurrence status were excluded. The primary outcome measured was the degree of pathologic response. Logistic regression was used to adjust for covariates. RESULTS: Of the 135 patients eligible in the study cohort, 39% were female and 61% were male. Regarding initial clinical stage, 43% were stage II and 57% were stage III. A total of 29% had a pCR, 43% had partial pathologic response, and 28% had no response to neoadjuvant treatment. Tumor location ranged from 0 to 13 cm from the anal verge. Longitudinal tumor length was recorded in 111 patients, facilitating the calculation of mean tumor distance from the anal verge. This ranged from 0 to 15.5 cm. Univariate and multivariable analyses were completed using pCR as a primary outcome. No statistically significant difference was noted based on tumor location, regardless of measurement approach. CONCLUSIONS: Anatomic location of cancer of the rectum does not affect pCR after neoadjuvant therapy and subsequent surgical resection. Published by Elsevier Inc.
Authors: Nicholas J Battersby; Peter How; Brendan Moran; Sigmar Stelzner; Nicholas P West; Graham Branagan; Joachim Strassburg; Philip Quirke; Paris Tekkis; Bodil Ginnerup Pedersen; Mark Gudgeon; Bill Heald; Gina Brown Journal: Ann Surg Date: 2016-04 Impact factor: 12.969
Authors: Dawn Armstrong; Soundouss Raissouni; Julie Price Hiller; Jamison Mercer; Erin Powell; Anthony MacLean; Maria Jiang; Corinne Doll; Rachel Goodwin; Eugene Batuyong; Kevin Zhou; Jose G Monzon; Patricia A Tang; Daniel Y Heng; Winson Y Cheung; Michael M Vickers Journal: Clin Colorectal Cancer Date: 2015-06-18 Impact factor: 4.481
Authors: Ariella Kleiman; Ahmed Al-Khamis; Ali Farsi; Abbas Kezouh; Te Vuong; Philip H Gordon; Carol-Ann Vasilevsky; Nancy Morin; Julio Faria; Gabriela Ghitulescu; Marylise Boutros Journal: J Gastrointest Surg Date: 2015-04-10 Impact factor: 3.452
Authors: Julio Garcia-Aguilar; Zhenbin Chen; David D Smith; Wenyan Li; Robert D Madoff; Peter Cataldo; Jorge Marcet; Carlos Pastor Journal: Ann Surg Date: 2011-09 Impact factor: 12.969
Authors: Angelo Restivo; Luigi Zorcolo; Ivana Maria Francesca Cocco; Romina Manunza; Carla Margiani; Luigi Marongiu; Giuseppe Casula Journal: Ann Surg Oncol Date: 2012-09-26 Impact factor: 5.344
Authors: Fiona G M Taylor; Philip Quirke; Richard J Heald; Brendan Moran; Lennart Blomqvist; Ian Swift; David J Sebag-Montefiore; Paris Tekkis; Gina Brown Journal: Ann Surg Date: 2011-04 Impact factor: 12.969
Authors: Hak-Mien Quah; Joanne F Chou; Mithat Gonen; Jinru Shia; Deborah Schrag; Leonard B Saltz; Karyn A Goodman; Bruce D Minsky; W Douglas Wong; Martin R Weiser Journal: Cancer Date: 2008-07-01 Impact factor: 6.860